Eli Lilly plans to acquire Centessa Pharmaceuticals, which has been conducting a midstage clinical trial of its lead drug. By Rebecca Robbins Eli Lilly reached a deal on Tuesday to buy Centessa ...

One of Eli Lilly & Co.’s most highly anticipated experimental medicines helped diabetic patients lose more weight than any drug currently on the market, underscoring its potential in the increasingly ...

Eli Lilly said its next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight. The drug ...

With shares up 20% over the past 12 months, Eli Lilly appears to have come out on top in the battle to dominate the weight-loss drug market, with rival Novo Nordisk sinking 52% over the same period.

In a surprising move, Eli Lilly’s stock has been downgraded by HSBC analysts who argue that the heavily hyped weight-loss-drug market is due for a correction — and that the middle-class Americans who ...

Eli Lilly’s LLY-2.09%decrease; red down pointing triangle experimental weight-loss drug retatrutide met the primary and key secondary endpoints in a trial, showing significant improvements in weight ...

Eli Lilly (LLY) shares slipped in the premarket on Tuesday after HSBC downgraded the weight loss drugmaker to Reduce from Hold, issuing the pharma giant’s only sell-equivalent rating on Wall Street, ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Diabetes patients taking ...

As Eli Lilly begins to take the next generation of obesity drugs to regulators this year, a lower-profile collaboration suggests the Big Pharma still thinks it could find future success from a more ...

Matthew Herper covers medical innovation — both its promise and its perils. Everything changed with a white envelope. On Dec. 20, 2018, Jacob Van Naarden, the chief operating officer of a biotech ...

acvln8inpaeornsagl ioivtIoaaioda g .rarw.tf nirlespen d e- u uayr1 tie slseaLn pdx hsaeaae diin ostr tm gpiaoeeldontne osd Ee$wl cu.C iny l huhsroasnnrrnntbs imc otti ...

With the success of GLP-1-based drugs, pharmaceutical companies are aggressively pursuing next-generation versions that could provide patients with more refined options for controlling diabetes and ...